TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Resverlogix ( (TSE:RVX) ) has issued an announcement.
Resverlogix Corp. held its Annual Meeting of Shareholders in Calgary, where four board members were elected with high approval rates. The shareholders also approved all resolutions presented in the meeting’s notice. This meeting underscores the company’s continued focus on advancing its clinical programs and strategic partnerships, particularly in the commercialization of its lead candidate, apabetalone, which is expected to impact the treatment of cardiovascular diseases and related conditions.
More about Resverlogix
Resverlogix is a Calgary-based biotechnology company founded in 2001, specializing in epigenetics. The company focuses on developing first-in-class therapies aimed at treating chronic diseases, particularly through regulating disease-causing gene expressions. Their lead candidate, apabetalone, is being evaluated for cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. Resverlogix has partnered with EVERSANA for the commercialization of apabetalone in Canada and the United States.
Average Trading Volume: 73,848
Technical Sentiment Signal: Sell
Current Market Cap: C$11.37M
Learn more about RVX stock on TipRanks’ Stock Analysis page.